|
業務類別
|
Biotechnology |
|
業務概覽
|
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy. |
| 公司地址
| 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304 |
| 電話號碼
| +1 650 391-9740 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.bridgebio.com |
| 員工數量
| 839 |
| Dr. Neil Kumar, PhD |
Director; Chief Executive Officer of the Company and Eidos Therapeutics, Inc. |
美元 987.54K |
24/02/2026 |
| Dr. Thomas Trimarchi, PhD |
Principal Financial Officer and President |
美元 643.65K |
24/02/2026 |
| Ms. Maricel M. Apuli |
Chief Accounting Officer |
-- |
24/02/2026 |
|
|
| Dr. Charles J. Homcy,M.D. |
Lead director |
24/02/2026 |
| Mr. Fred Hassan |
Lead Independent Director |
24/02/2026 |
| Dr. Frank P. McCormick, D.Sc.,F.R.S.,PhD |
Director |
24/02/2026 |
| Mr. James C. Momtazee |
Independent Director |
24/02/2026 |
| Dr. Randal W. Scott,PhD |
Independent Director |
24/02/2026 |
| Dr. Eric Aguiar, M.D. |
Independent Director |
24/02/2026 |
| Mr. Ali J. Satvat |
Independent Director |
24/02/2026 |
| Mr. Douglas A. Dachille |
Independent Director |
24/02/2026 |
| Dr. Neil Kumar, PhD |
Director; Chief Executive Officer of the Company and Eidos Therapeutics, Inc. |
24/02/2026 |
| Ms. Jennifer E. Cook |
Independent Director |
24/02/2026 |
| Mr. Ronald J. Daniels |
Independent Director |
24/02/2026 |
| Dr. Andrew W. Lo, PhD |
Independent Director |
24/02/2026 |
| Dr. Hannah A. Valantine, M.D. |
Independent Director |
24/02/2026 |
| Ms. Andrea John Ellis |
Independent Director |
24/02/2026 |
|
|
|
|
